Every 8-K that Bioventus Inc. (BVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BVS filings page.
Bioventus Inc. reported strong second-quarter 2026 results, with net sales of $153.2 million, up from $147.7 million a year earlier. Net income attributable to Bioventus rose to $33.4 million from $7.5 million, aided in part by removal of a $24.6 million valuation allowance on deferred tax assets. GAAP diluted EPS increased to $0.47 from $0.11, while non-GAAP diluted EPS was $0.22 versus $0.21. Adjusted EBITDA reached $35.3 million, compared with $33.8 million, and cash from operations was $19.9 million.
The company made a discretionary $20.0 million principal prepayment on its term loan, reducing long-term debt and future interest expense. For full-year 2026, Bioventus reaffirmed guidance for net sales of $600–$610 million, adjusted EPS of $0.75–$0.79, and cash from operations of $84–$89 million. Following a recent unsolicited acquisition proposal and other expressions of interest, the board formed an independent committee, advised by Evercore and Latham & Watkins, to review strategic alternatives, including a potential sale or continued standalone execution, with no timetable or assurance of any transaction.
Bioventus Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. A total of 75,279,174 shares of Class A and Class B common stock were present in person or by proxy, representing approximately 90.23% of outstanding shares entitled to vote as of the April 6, 2026 record date.
Stockholders elected all nominated directors to the Board to serve until the 2027 annual meeting and until their successors are elected and qualified, or earlier death, resignation or removal. The filing lists individual vote totals and broker non-votes for each director.
Stockholders also ratified the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,228,481 shares voting for, 5,021 against and 45,672 abstaining, and no broker non-votes reported on this item.
Bioventus Inc. reports U.S. regulatory and reimbursement changes affecting its Exogen Ultrasound Bone Healing System but keeps its 2026 outlook unchanged. The FDA issued a final order on April 16, 2026 reclassifying non-invasive bone growth stimulators, including Exogen, from higher-risk Class III to Class II devices.
Following this, CMS updated billing requirements and the Medicare fee schedule for non-invasive bone growth stimulators billed under HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026. Bioventus currently does not expect the revised reimbursement rates for Exogen to have a material impact on fiscal 2026 results and is reiterating its financial guidance, while continuing to evaluate potential longer-term effects of any current or future CMS actions.
Bioventus Inc. reported stronger first-quarter 2026 results, with revenue of $132.1 million, up 6.6% year over year, driven by growth across Pain Treatments, Surgical Solutions and Restorative Therapies.
Net income attributable to Bioventus was $3.1 million, reversing a $2.6 million loss a year earlier, and GAAP diluted EPS improved to $0.04 from a $0.04 loss. Non-GAAP diluted EPS rose to $0.15 from $0.08, supported by higher gross profit, lower interest expense and a 24% increase in Adjusted EBITDA to $23.9 million.
Cash from operations was $8.9 million, compared with a $19.3 million outflow in the prior-year quarter. The company made a $22.0 million discretionary term-loan prepayment and raised full-year 2026 guidance for Adjusted EPS to $0.75–$0.79 and cash from operations to $84–$89 million, while reaffirming net sales guidance of $600–$610 million, implying approximately 6%–7% growth.
Bioventus Inc. reported a strong turnaround for 2025, moving from a prior-year loss to profitability and guiding to further growth in 2026. Fourth-quarter 2025 revenue was $157.9 million, up 2.8% reported and 10.0% on an organic basis, with GAAP earnings of $0.21 per diluted share and non-GAAP earnings of $0.24.
For full-year 2025, revenue was $568.1 million, down 0.9% reported but up 7.5% organically after divesting the Advanced Rehabilitation Business. Net income attributable to Bioventus was $22.7 million versus a $36.1 million loss last year, and Adjusted EBITDA rose 6.8% to $116.3 million. Adjusted EPS increased 21.4% to $0.68.
The company generated $74.7 million of cash from operations in 2025, up 92%, and reduced debt by $29 million in the fourth quarter, strengthening its balance sheet. For 2026, Bioventus expects net sales of $600–$610 million (about 6–7% growth), Adjusted EPS of $0.73–$0.77 (about 7–13% growth), and cash from operations of $82–$87 million.
Bioventus Inc. reported that its Board of Directors appointed Ajay Dhankhar, PhD, as a Class II director effective November 14, 2025. He will serve until the company’s 2026 annual stockholders meeting or until a successor is selected and qualified. Dr. Dhankhar is currently Chief Corporate Development & Strategy Officer at Smith & Nephew plc and has extensive experience in healthcare advisory and life sciences strategy, including senior roles at Lazard and McKinsey & Company.
The appointment is made under a Stockholders Agreement that allows certain Smith & Nephew stockholders to designate up to two directors, and Dr. Dhankhar is their second designee alongside Philip G. Cowdy. Bioventus states that Dr. Dhankhar will not receive compensation for his Board service and that he has no family relationships with company insiders and no disclosable related-party transactions.
Bioventus Inc. (BVS) reported results for the three and nine months ended September 27, 2025. The company announced these financial results via a press release furnished as Exhibit 99.1 to a Form 8-K.
The information in Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated. The filing also lists Exhibit 104, the cover page Inline XBRL data.
Bioventus Inc. (BVS) entered into a Credit Agreement dated July 31, 2025, establishing a $100 million revolving credit facility and a $300 million first lien term loan A facility, and drew $30 million under the revolver on the Closing Date.
Key terms:
- Total facilities: $400 million ($100M revolver, $300M term loan)
- Maturity: July 31, 2030
- Interest: Term SOFR plus initial margin 2.50% (margin thereafter adjusted quarterly by consolidated total net leverage bands)
- Amortization: Term loan amortizes 5% of original principal annually; balance due at maturity
- Fees: Revolver commitment fee 0.30% (stepdown 0.10% if leverage <2.50x); revolver includes $7.5M letter of credit and $7.5M swingline sub-facilities
- Covenants: secured by substantially all assets; maximum consolidated total net leverage 4.00x (through Q4 2025) then 3.50x thereafter (temporary 0.50x election for certain acquisitions); consolidated interest coverage >=2.50x starting Q3 2025
Bioventus Inc. (BVS) filed a Form 8-K to report that on 30 Jul 2025 the U.S. FDA granted 510(k) clearance for two Peripheral Nerve Stimulation (PNS) devices, TalisMann™ and StimTrial™. The decision permits immediate U.S. marketing without additional clinical trials, expanding Bioventus’ portfolio beyond orthobiologics and bone-healing systems.
No revenue, margin or guidance figures were disclosed, yet management signals a new addressable market in neuromodulation. Clearance could diversify revenue streams and leverage the company’s existing sales infrastructure; however, launch timing, pricing, reimbursement and market-share expectations remain unspecified.
- Item reported: 8.01 – Other Events
- Regulatory milestone: FDA 510(k) clearance
- Products affected: TalisMann & StimTrial PNS devices
- Potential impact: accelerates entry into U.S. PNS market, incremental growth driver